- Execution rate: 1:1 (1 share - 1 voting right)
- Execution time: 05/04/2026 tentatively
- Execution venue: to be announced in the invitation letter
- Content:
+ Report on 2025 business performance and 2026 business plan;
+ 2025 Audited financial statements;
+ 2025 Profit distribution plan;
+ Selection of the auditing firm for 2026;
+ Other matters within the authority of the General Meeting;
Coordination details and procedures for corporate action processing for holders of the above securities between VSDC, the Securities registering institution and depository members are specified in the Guideline on corporate action processing for securities holders at VSDC.
Da Nang Pharmaceutical - Medical Equipment Joint Stock Company and the parties involved in the process of preparing the dossier, documents of corporate action processing are fully responsible before the law for the legality, accuracy, truthfulness and completeness of the dossier; Institutions and individuals participating in the confirmation of records and documents shall be legally responsible within the scope related to such records and documents as prescribed in Clause 1, Article 11a of the Securities Law No. 54/2019/QH14 dated 26/11/2019, supplemented by Clause 4, Article 1 of Law No. 56/2024/QH15 dated 29/11/2024.